Precigen (PGEN) Debt Ratio (2012 - 2026)

Precigen (PGEN) posted quarterly Debt Ratio of 0.67 for Q1 2026, up 12.59% quarter-over-quarter from 0.6 in Q4 2025.

Precigen (PGEN) Debt Ratio (2012 - 2026) Analysis & Trends

Precigen (PGEN) has reported Debt Ratio for 14 consecutive years, with 0.67 the latest figure, recorded in Q1 2026.

In Q1 2026, Debt Ratio changed N/A year-over-year to 0.67; the TTM figure through Mar 2026 stood at 0.67 (changed N/A YoY), while the FY2025 annual figure was 0.6, changed N/A from the prior year.
Debt Ratio advanced to 0.67 in Q1 2026 per PGEN's latest filing, from 0.6 in the prior quarter.
Across five years, Debt Ratio topped out at 0.67 in Q1 2026 and bottomed at 0.06 in Q1 2023.
Historically, Debt Ratio has averaged 0.48 across 4 years, with a median of 0.57 in 2025.
Annual changes were most pronounced in 2022 — Debt Ratio soared 40.36% — and 2023, when it slumped 90.46%.
Precigen's Debt Ratio stood at 0.4 in 2022, then slumped by 85.71% to 0.06 in 2023, then jumped by 947.31% to 0.6 in 2025, then gained by 12.59% to 0.67 in 2026.
Business Quant data shows PGEN's Debt Ratio at 0.67 in Q1 2026, 0.6 in Q4 2025, and 0.54 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	0.05
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	0.12
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	0.47
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	0.26
10	Precigen	2.18 Bn	2.18 Bn	52.17 Mn	0.55

Download Data